Profile data is unavailable for this security.
About the company
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.
- Revenue in USD (TTM)0.00
- Net income in USD-8.69m
- Incorporated2014
- Employees8.00
- LocationDermata Therapeutics Inc3525 Del Mar Heights Rd., #322SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 223-0882
- Fax+1 (302) 636-5454
- Websitehttps://www.dermatarx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| International Stem Cell Corp | 7.83m | -327.00k | 907.70k | 29.00 | -- | -- | -- | 0.1159 | -0.0409 | -0.0409 | 0.9785 | 0.0045 | 1.46 | 2.53 | 11.87 | 270,069.00 | -5.81 | -29.22 | -68.13 | -73.82 | 58.58 | 59.49 | -3.97 | -21.01 | 0.4672 | -6.06 | 0.9898 | -- | -4.78 | -6.82 | 60.42 | -- | -34.45 | -- |
| GRI Bio Inc | 0.00 | -12.77m | 947.93k | 4.00 | -- | 0.138 | -- | -- | -349.68 | -349.68 | 0.00 | 11.38 | 0.00 | -- | -- | 0.00 | -382.23 | -192.93 | -869.57 | -353.99 | -- | -- | -- | -37,650.49 | -- | -16.80 | 0.00 | -- | -- | -- | -85.61 | -- | 29.46 | -- |
| Herborium Group, Inc. | 340.33k | -318.65k | 1.09m | 2.00 | -- | -- | -- | 3.21 | -0.3492 | -0.3492 | 0.3672 | -1.16 | 2.32 | 3.89 | 25.94 | -- | -216.97 | -490.56 | -- | -- | 58.31 | 56.36 | -93.63 | -186.81 | 0.0331 | -39.14 | -- | -- | 19.45 | -18.15 | 120.44 | -- | -- | -- |
| LadRx Corp | 0.00 | 1.66m | 1.11m | 2.00 | 0.6504 | 3.21 | 0.663 | -- | 3.44 | 3.44 | 0.00 | 0.6973 | 0.00 | -- | -- | 0.00 | 96.28 | -58.97 | -- | -78.44 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 106.96 | -- | -- | -- |
| Actavia Life Sciences Inc | 0.00 | -406.65k | 1.23m | 1.00 | -- | -- | -- | -- | -0.0005 | -0.0005 | 0.00 | -0.0028 | 0.00 | -- | -- | 0.00 | -805.97 | -158.17 | -- | -- | -- | -- | -- | -- | -- | -5.63 | -- | -- | -- | -- | -547.04 | -- | -- | -- |
| Dermata Therapeutics Inc | 0.00 | -8.69m | 1.33m | 8.00 | -- | 4.13 | -- | -- | -24.67 | -24.67 | 0.00 | 0.5717 | 0.00 | -- | -- | 0.00 | -120.05 | -- | -146.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.90 | -- | -- | -- |
| Salarius Pharmaceuticals Inc | 0.00 | -8.92m | 1.36m | 2.00 | -- | 0.3362 | -- | -- | -21.71 | -21.71 | 0.00 | 6.77 | 0.00 | -- | -- | 0.00 | -119.38 | -69.27 | -193.68 | -79.89 | -- | -- | -- | -675.70 | -- | -- | 0.031 | -- | -- | -- | 60.32 | -- | -- | -- |
| Manuka Inc | 671.00k | -1.14m | 1.46m | 4.00 | -- | -- | -- | 2.17 | -0.0128 | -0.0128 | 0.0066 | -0.0124 | 2.41 | 0.9412 | 37.28 | 167,750.00 | -410.43 | -463.75 | -- | -- | 88.08 | -- | -170.04 | -732.15 | 0.0194 | -- | -- | -- | -- | -- | -854.23 | -- | -- | -- |
| 180 Life Sciences Corp | 0.00 | -16.24m | 1.47m | 4.00 | -- | -- | -- | -- | -41.54 | -41.54 | 0.00 | -1.12 | 0.00 | -- | -- | 0.00 | -176.90 | -42.39 | -354.57 | -56.41 | -- | -- | -- | -- | -- | -385.88 | -- | -- | -- | -- | 48.52 | -- | -- | -- |
| Drazcanna Inc | 2.05m | -5.71m | 1.47m | -- | -- | -- | -- | 0.7192 | -0.7024 | -0.7024 | 0.2492 | 0.1004 | 0.685 | -- | 23.88 | -- | -191.19 | -- | -643.20 | -- | -11.20 | -- | -279.10 | -- | -- | -33.04 | 0.2445 | -- | -- | -- | -- | -- | -- | -- |
| Virpax Pharmaceuticals Inc | 0.00 | -16.89m | 1.58m | 7.00 | -- | -- | -- | -- | -14.42 | -14.42 | 0.00 | -1.04 | 0.00 | -- | -- | 0.00 | -156.21 | -87.52 | -241.52 | -116.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.84 | -- | -- | -- |
| Seelos Therapeutics Inc | 1.97m | -27.12m | 1.59m | 10.00 | -- | -- | -- | 0.804 | -44.59 | -44.59 | 2.16 | -17.36 | 0.1449 | -- | 2.24 | 131,600.00 | -198.99 | -180.05 | -- | -386.76 | -- | -- | -1,373.61 | -9,612.88 | -- | -- | -- | -- | -- | -- | 48.48 | -- | -- | -- |
| CNS Pharmaceuticals Inc | 0.00 | -17.46m | 1.76m | 3.00 | -- | -- | -- | -- | -179.17 | -179.17 | 0.00 | -20.76 | 0.00 | -- | -- | 0.00 | -384.86 | -132.47 | -- | -185.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -23.42 | -- | -- | -- |
| Hi-Great Group Holding Co | 101.27k | -113.56k | 1.78m | -- | -- | -- | -- | 17.58 | -0.0011 | -0.0011 | 0.001 | -0.0011 | 0.7887 | 0.8027 | -- | -- | -88.44 | -- | -- | -- | 48.60 | -- | -112.14 | -- | 0.0197 | -48.81 | -- | -- | -47.32 | -- | -3,789.70 | -- | -- | -- |
Data as of Jul 05 2024. Currency figures normalised to Dermata Therapeutics Inc's reporting currency: US Dollar USD
1.13%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Two Sigma Securities LLCas of 31 Mar 2024 | 1.33k | 0.30% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 1.28k | 0.29% |
| Citadel Securities LLCas of 31 Mar 2024 | 1.17k | 0.26% |
| Geode Capital Management LLCas of 31 Mar 2024 | 816.00 | 0.18% |
| Tower Research Capital LLCas of 31 Mar 2024 | 383.00 | 0.09% |
| Wells Fargo Clearing Services LLCas of 31 Mar 2024 | 46.00 | 0.01% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 1.00 | 0.00% |
| The Northwestern Mutual Life Insurance Co. (Invt Port)as of 31 Mar 2024 | 1.00 | 0.00% |
| Virtu Americas LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| Armistice Capital LLCas of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
